含有分子内佐剂的CIC蛋白表达及免疫活性初步研究

doi:10.16431/j.cnki.1671-7236.2017.12.031

摘要/Abstract

摘要：

为了研究含有分子内佐剂的CTB-IsdBid-Clfais（CIC）蛋白表达及其免疫活性，试验采用重叠PCR方法将分子内佐剂CTB与IsdBid-Clfais基因串联，并将CTB-IsdBid-Clfais（CIC）插入到表达载体pET-32a（+）中，构建pET-32a（+）-CTB-IsdBid-Clfais重组质粒，将鉴定正确的重组质粒转化到大肠杆菌BL21感受态细胞中表达目的蛋白CIC，利用Western blotting方法对其进行鉴定，并以ELISA方法检测CIC蛋白的免疫活性。结果发现，试验成功扩增了2 072 bp的目的基因CIC，并将CIC正确连接到pET-32a（+）载体上，构建了pET-32a（+）-CTB-IsdBid-Clfais重组质粒；Western blotting结果证实，该重组质粒能够在大肠杆菌BL21感受态细胞中正确表达CIC蛋白，分子质量大小为95.9 ku；ELISA结果显示，CIC试验组与IsdBid、Clfais蛋白组间均无显著差异（P>0.05），与BSA组间差异极显著（P<0.01）。综上所述，本研究成功构建了pET-32a（+）-CTB-IsdBid-Clfais重组质粒，该质粒在大肠杆菌BL21中成功表达了CIC蛋白，且CIC能与IsdBid、Clfais免疫小鼠血清发生反应，具有较强的免疫活性。

关键词: 金黄色葡萄球菌; CTB-IsdBid-Clfais蛋白; 蛋白表达; 免疫原性

Abstract:

To express CTB-IsdBid-Clfais(CIC) protein and evaluate its immunogenicity, CTB (as a molecular adjuvant) could be tandem linked with IsdBid-Clfais gene by the overlapping PCR method, then CTB-IsdBid-Clfais(CIC) was inserted into pET-32a(+) vector to construct recombinant plasmids pET-32a(+)-CTB-IsdBid-Clfais. The recombinant plasmids pET-32a(+)-CTB-IsdBid-Clfais were transformed into Escherichia coli (E.coli) BL21 to express the CTB-IsdBid-Clfa(CIC) protein, the CIC expression protein and its immune activity were detected by Western blotting and ELISA,respectively. The results showed that the length of CIC gene were 2 072 bp, and CIC was correctly inserted into the pET-32a(+) plasmids, the pET-32a(+)-CTB-IsdBid-Clfais recombinant plasmids were successfully constructed. Western blotting result confirmed that the molecular weight of CIC proteins was 95.9 ku, which were correctly expressed by E.coli BL21 with pET-32a (+)-CTB-IsdBid-Clfais plasmids. ELISA results showed that there was no significant difference among the CIC, IsdBid and Clfais protein groups (P>0.05), and there was extremely significant difference between CIC and BSA protein groups (P<0.01). In conclusion, the pET-32a(+)-CTB-IsdBid-Clfais recombinant plasmids were successfully constructed, CIC proteins were correctly expressed, and were able to react with serum from mice immunized with IsdBid and Clfais,respectively,therefore, CIC proteins had strong immune activity.

Key words: Staphylococcus aureus; CTB-IsdBid-Clfais protein; protein expression; immunogenicity

中图分类号:

S852.4

张少铎, 来怡君, 姜辉, 程欣然, 叶玉婷, 何溪雨, 徐乐, 宋佰芬, 于立权, 崔玉东, 马金柱. 含有分子内佐剂的CIC蛋白表达及免疫活性初步研究[J]. 《中国畜牧兽医》, 2017, 44(12): 3612-3617.

ZHANG Shao-duo, LAI Yi-jun, JIANG Hui, CHENG Xin-ran, YE Yu-ting, HE Xi-yu, XU Le, SONG Bai-fen, YU Li-quan, CUI Yu-dong, MA Jin-zhu. Study on Expression and Preliminary Immunocompetence of CIC Protein Containing Molecular Adjuvants[J]. , 2017, 44(12): 3612-3617.

参考文献

[1] Grothe C, Taminato M, Belasco A, et al. Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus:A systematic review and meta-analysis[J]. BMC Nephrol, 2016, 17(1):115.
[2] Melehani J H, Duncan J A. Inflammasome activation can mediate tissue-specific pathogenesis or protection in Staphylococcus aureus infection[J]. Curr Top Microbiol Immunol, 2016, 397:257-282.
[3] Kobayashi S D, Malachowa N, DeLeo F R. Pathogenesis of Staphylococcus aureus abscesses[J]. Am J Pathol,2015,185(6):1518-1527.
[4] Barkema H W, Schukken Y H, Zadoks R N. Invited review:The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis[J]. J Dairy Sci,2006, 89(6):1877-1895.
[5] Althaqafi A O, Matar M J, Moghnieh R, et al. Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia[J]. Infect Drug Resist, 2017, 10:49-55.
[6] 李娟. 牛源金黄色葡萄球菌耐药现状及药敏检测方法探讨[J]. 中国畜牧兽医, 2017, 33(3):64.
[7] Choo E J, Chambers H F. Treatment of methicillin-resistant Staphylococcus aureus bacteremia[J]. Infect Chemother, 2016, 48(4):267-273.
[8] Sowash M G, Uhlemann A C. Community-associated methicillin-resistant Staphylococcus aureus case studies[J]. Methods Mol Biol,2014,1085:25-69.
[9] Blanco N, Perencevich E, Li S S,et al. Effect of meteorological factors and geographic location on methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci colonization in the US[J]. PLoS One,2017,12(5):e0178254.
[10] Hu Q, Peng H, Rao X.Molecular events for promotion of vancomycin resistance in vancomycin intermediate Staphylococcus aureus[J]. Front Microbiol,2016,7:1601.
[11] Liu Q, Du X, Hong X, et al. Targeting surface protein SasX by active and passive vaccination to reduce Staphylococcus aureus colonization and infection[J]. Infect Immun,2015,83(5):2168-2174.
[12] Delfani S, Mohabati M A, Imani F A A, et al. Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA-IsdB-Hlg as a vaccine candidate[J]. Med Microbiol Immunol, 2016, 205(1):47-55.
[13] Pietrocola G, Nobile G, Rindi S, et al.Staphylococcus aureus manipulates innate immunity through own and host-expressed proteases[J]. Front Cell Infect Microbiol,2017,7:166.
[14] Jusko M, Potempa J, Kantyka T, et al. Staphylococcal proteases aid in evasion of the human complement system[J]. J Innate Immun, 2014,6(1):31-46.
[15] Kim H K, Thammavongsa V, Schneewind O, et al. Recurrent infections and immune evasion strategies of Staphylococcus aureus[J]. Curr Opin Microbiol, 2012, 15(1):92-99.
[16] Josefsson E, Hartford O, O'Brien L, et al. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant[J]. J Infect Dis, 2001, 184(12):1572-1580.
[17] 冯昊, 刘乐锋, 迟佳琦, 等. 金黄色葡萄球菌凝集因子A的免疫原性[J]. 生物工程学报, 2009, 25(8):1180-1186.
[18] Schaffer A C, Solinga R M, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model[J]. Infect Immun, 2006, 74(4):2145-2153.
[19] Kuklin N A, Clark D J, Secore S, et al. A novel Staphylococcus aureus vaccine:Iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model[J]. Infect Immun, 2006, 74(4):2215-2223.
[20] Yu L,Fan Z,Ma J,et al.Cross-protective effect of a novel multi-antigen-chimeric vaccine against Streptococcus and Staphylococcus aureus infection in mice[J]. J Med Microbiol, 2014,63(Pt12):1732-1740.
[21] Meza-Sánchez D, Pérez-Montesinos G, Sánchez-García J, et al. Intradermal immunization in the ear with cholera toxin and its non-toxic β subunit promotes efficient Th1 and Th17 differentiation dependent on migrating DCs[J].Eur J Immunol, 2011, 41(10):2894-2904.
[22] Lee J B,Jang J E,Song M K,et al. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to by stander antigens[J]. PLoS One, 2009, 4(4):e5190.
[23] Lin L, Ibrahim A S, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice[J]. PLoS Pathog, 2009, 5(12):e1000703.
[24] Montgomery C P, Daniels M, Zhao F, et al. Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A[J]. Infect Immun,2014, 82(5):2125-2134.